Drug Trial Radar · NCT03897205
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Apr 30, 2019
Primary completion
May 28, 2022
Study completion Nov 16, 2022
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an active or chronic active antibody mediated rejection (AMR) after being kidney transplanted. The purpose was also to investigate and compare safety for these two treatments.
Conditions
- Kidney Transplant Rejection
Interventions
ImlifidaseDrug
Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
Plasma ExchangeOther
The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of TreatmentTime frame: Start of treatment until 5 days following start of treatment
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Brigham and Women Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
New York University Grossman School of Medicine
New York, New York
Royal Adelaide Hospital
Adelaide, Australia
Royal Prince Alfred Hospital
Sydney, Australia
The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW
Vienna, Austria
Hôpital Pellegrin
Bordeaux, France
CHU Grenoble Alpes - Néphrologie, dialyse et transplantation
Grenoble, France
Hôpital Saint-Louis. Service de Néphrologie et Transplantation
Paris, France
Hôpital Necker - Service de Néphrologie - Transplantation
Paris, France
Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care
Berlin, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.